Novel pyrimidine-based CXCR2 chemokine receptor antagonists

Abstract

Novel derivatives of 6-amino-2-benzylthio-4-hydroxypyrimidine are claimed as CXCR2 chemokine receptor antagonists useful in the treatment of chronic obstructive pulmonary disease, asthma and allergic rhinitis, inflammatory bowel disease, psoriasis, osteoarthritis, rheumatoid arthritis and cancer. The claimed compounds are monocylic analogues of previously described purine derivatives, at least some of which display reasonable affinity for the CXCR2 receptor.

• chronic obstructive pulmonary disease (COPD)
• CXCR2 chemokine receptor
• growth-related oncogene-α (GRO-α)
• IL-8
• inflammation
• neutrophil